These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 26886336

  • 1. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
    Iga K.
    J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
    [Abstract] [Full Text] [Related]

  • 2. Simulation of Metabolic Drug-Drug Interactions Perpetrated by Fluvoxamine Using Hybridized Two-Compartment Hepatic Drug-Pool-Based Tube Modeling and Estimation of In Vivo Inhibition Constants.
    Iga K.
    J Pharm Sci; 2015 Oct; 104(10):3565-77. PubMed ID: 26099559
    [Abstract] [Full Text] [Related]

  • 3. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
    Iga K, Kiriyama A.
    J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
    [Abstract] [Full Text] [Related]

  • 4. Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug-Drug Interaction.
    Iga K, Kiriyama A.
    Biol Pharm Bull; 2017 Dec 01; 40(12):2024-2037. PubMed ID: 28993551
    [Abstract] [Full Text] [Related]

  • 5. Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug-drug interactions in rat liver.
    Iwasaki S, Hirabayashi H, Funami M, Amano N.
    Xenobiotica; 2017 Jun 01; 47(6):488-497. PubMed ID: 27435455
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel.
    Nishihara M, Yamasaki H, Czerniak R, Jenkins H.
    Eur J Drug Metab Pharmacokinet; 2019 Apr 01; 44(2):217-227. PubMed ID: 30361928
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel.
    Tornio A, Filppula AM, Backman JT.
    Basic Clin Pharmacol Toxicol; 2022 Jan 01; 130 Suppl 1():48-59. PubMed ID: 34410044
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil.
    Iga K, Kiriyama A.
    Clin Pharmacokinet; 2024 Jan 01; 63(1):43-56. PubMed ID: 37921907
    [Abstract] [Full Text] [Related]

  • 17. P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms.
    McDonald MG, Au NT, Rettie AE.
    Drug Metab Dispos; 2015 Nov 01; 43(11):1661-9. PubMed ID: 26296708
    [Abstract] [Full Text] [Related]

  • 18. Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.
    Lutz JD, VandenBrink BM, Babu KN, Nelson WL, Kunze KL, Isoherranen N.
    Drug Metab Dispos; 2013 Dec 01; 41(12):2056-65. PubMed ID: 23785064
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.